The study will be performed in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger levels such as cyclic guanosine monophosphate.
Dr Trevor Hallam, Palatin’s executive vice president for R&D, said: “We are excited to begin clinical trials of PL-3994, a compound developed by Palatin scientists that has the potential to become a new tool for physicians to advance the treatment of congestive heart failure (CHF). CHF is the single most common cause of hospitalization in the US for patients older than 65 years of age and an underserved medical condition.”